Pharmosa Biopharm Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	50.52	314.5	-	-	-
Gross Profit	13.42	314.5	-	-	-
Selling, General & Admin	52.63	40.35	29.22	18.32	12.11
Research & Development	283.63	276.97	242.31	240.81	175.31
Operating Expenses	336.26	317.32	271.53	259.12	187.42
Operating Income	-322.84	-2.82	-271.53	-259.12	-187.42
Interest Expense	-3.06	-2.86	-0.65	-1.21	-3.86
Interest & Investment Income	28.4	9.53	0.5	0.1	0.04
Earnings From Equity Investments	3.62	5.5	3.93	0.66	4.63
Currency Exchange Gain (Loss)	-6.68	-6.68	1.02	0.2	0.96
Other Non Operating Income (Expenses)	7.63	5.79	0.23	2.89	3.96
Pretax Income	-292.93	8.46	-266.51	-256.48	-181.7
Net Income	-292.93	8.46	-266.51	-256.48	-181.7
Net Income to Common	-292.93	8.46	-266.51	-256.48	-181.7
Shares Outstanding (Basic)	124	113	99	85	48
Shares Outstanding (Diluted)	124	113	99	85	48
Shares Change (YoY)	13.14%	15.09%	16.02%	78.34%	-
EPS (Basic)	-2.37	0.07	-2.70	-3.02	-3.82
EPS (Diluted)	-2.37	0.07	-2.70	-3.02	-3.82
Free Cash Flow	-454.84	-39.04	-268.47	-240.57	-188.5
Free Cash Flow Per Share	-3.68	-0.34	-2.72	-2.83	-3.96
Gross Margin	26.57%	100.00%	-	-	-
Operating Margin	-639.02%	-0.90%	-	-	-
Profit Margin	-579.83%	2.69%	-	-	-
Free Cash Flow Margin	-900.31%	-12.41%	-	-	-
EBITDA	-313.82	2.99	-266.24	-254.73	-184.2
EBITDA Margin	-	0.95%	-	-	-
D&A For EBITDA	9.02	5.81	5.3	4.39	3.22
EBIT	-322.84	-2.82	-271.53	-259.12	-187.42
EBIT Margin	-	-0.90%	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.